http://iccvam.niehs.nih.gov/methods/invidocs/guidance/iv_guide.pdf

   Table of Contents (HTML) NIH Publication No: 01-4500 Guidance Document
   on Using In Vitro Data to Estimate In Vivo Starting Doses for Acute
   Toxicity Based on Recommendations from an International Workshop
   Organized by the Interagency Coordinating Committee on the Validation
   of Alternative Methods (ICCVAM) and the National Toxicology Program
   (NTP) Interagency Center for the Evaluation of Alternative
   Toxicological Methods (NICEATM) National Institute of Environmental
   Health Sciences National Institutes of Health U.S. Public Health
   Service Department of Health and Human Services THE INTERAGENCY
   COORDINATING COMMITTEE ON THE VALIDATION OF ALTERNATIVE METHODS AND THE
   NTP INTERAGENCY CENTER FOR THE EVALUATION OF ALTERNATIVE TOXICOLOGICAL
   METHODS The Interagency Coordinating Committee on the Validation of
   Alternative Methods (ICCVAM) was established in 1997 by the Director of
   the National Institute of Environmental Health Sciences (NIEHS) to
   implement NIEHS directives in Public Law 103-43. P.L. 103-43 directed
   NIEHS to develop and validate new test methods, and to establish
   criteria and processes for the validation and regulatory acceptance of
   toxicological testing methods. P. L. 106-545, the ICCVAM Authorization
   Act of 2000, established ICCVAM as a permanent committee. The Committee
   is composed of representatives from 15 Federal regulatory and research
   agencies and programs that generate, use, or provide information from
   toxicity test methods for risk assessment purposes. The Committee
   coordinates cross-agency issues relating to development, validation,
   acceptance, and national/international harmonization of toxicological
   test methods. The National Toxicology Program Interagency Center for
   the Evaluation of Alternative Toxicological Methods (Center) was
   established in 1998 to provide operational support for the ICCVAM, and
   to carry out committee- related activities such as peer reviews and
   workshops for test methods of interest to Federal agencies. The Center
   and ICCVAM coordinate the scientific review of the validation status of
   proposed methods and provide recommendations regarding their usefulness
   to appropriate agencies. The NTP Center and ICCVAM seek to promote the
   validation and regulatory acceptance of toxicological test methods that
   will enhance agencies' abilities to assess risks and make decisions,
   and that will refine, reduce, and replace animal use. The ultimate goal
   is the validation and regulatory acceptance of new test methods that
   are more predictive of human and ecological effects than currently
   available methods. Additional Information Additional information can be
   found at the ICCVAM/Center Website: http://iccvam.niehs.nih.gov and in
   the publication: Validation and Regulatory Acceptance of Toxicological
   Test Methods, a Report of the ad hoc Interagency Coordinating Committee
   on the Validation of Alternative Methods (NIH Publication No. 97-3981,
   or you may contact the Center at telephone 919-541-3398, or by e-mail
   at iccvam@niehs.nih.gov. Specific questions about ICCVAM and the Center
   can be directed to the ICCVAM Co-chairs: Dr. William S. Stokes, NIEHS,
   EC-17, P.O. Box 12233 Research Triangle Park, NC, 27709; 919-541-7997
   stokes@niehs.nih.gov Dr. Richard N. Hill, US EPA, MC-7101, 401 M
   Street, SW Washington, DC, 20460; 202-260-2894 hill.richard@epa.gov
   ICCVAM Agencies and Programs Agency for Toxic Substances and Disease
   National Cancer Institute Registry National Institute of Environmental
   Health Consumer Product Safety Commission Sciences Department of
   Agriculture National Institutes of Health, Office of the Department of
   Defense Director Department of Energy National Institute of
   Occupational Safety and Department of Interior Health Department of
   Transportation National Library of Medicine Environmental Protection
   Agency Occupational Safety and Health Food and Drug Administration
   Administration Guidance Document on Using In Vitro Data to Estimate In
   Vivo Starting Doses for Acute Toxicity Based on Recommendations from an
   International Workshop Organized by the Interagency Coordinating
   Committee on the Validation of Alternative Methods (ICCVAM) and the
   National Toxicology Program (NTP) Interagency Center for the Evaluation
   of Alternative Toxicological Methods (NICEATM) National Toxicology
   Program P.O. Box 12233 Research Triangle Park, NC 27709 August 2001 NIH
   Publication No. 01-4500 National Institute of Environmental Health
   Sciences National Institutes of Health US Public Health Service
   Department of Health and Human Services ii Table of Contents List of
   Tables
   .......................................................................
   ......................................................................v
   List of Figures
   .......................................................................
   ....................................................................v
   List of Acronyms/Abbreviations
   .......................................................................
   ....................................vii Workshop Breakout Group
   .......................................................................
   .............................................xi Acknowledgements
   .......................................................................
   ..........................................................xii Preface
   .......................................................................
   .......................................................................
   .......xv 1.0 Introduction
   .......................................................................
   ...............................................................1 1.1
   Purpose and Scope of this Guidance Document
   .......................................................................
   .... 1 1.2 The Correlation Between Basal Cytotoxicity and Acute
   Lethality............................................... 1 1.3 In Vitro
   Determination of Starting Dose for In Vivo Tests
   ........................................................... 3 1.4
   Determination of In Vitro Test Performance
   Characteristics........................................................
   4 2.0 Elements of A Standard Test For Basal Cytotoxicity
   ...................................................................5
   2.1 Selection of Cell Lines /
   Cells..................................................................
   ..................................... 5 2.2 Recommended Measurement
   Endpoints for Basal Cytotoxicity
   .................................................. 6 2.3
   Recommendations for Cytotoxicity Test
   Protocols..............................................................
   ......... 7 3.0 Procedure for Qualifying a Cytotoxicity Test for use
   with the Registry of Cytotoxicity Prediction Model
   .......................................................................
   .............9 3.1 Procedure to Determine Whether a Candidate
   Cytotoxicity Test Can Use the RC Prediction
   Model..................................................................
   ...................................... 9 3.2 Recommended Reference
   Chemicals from the RC for Test Qualification
   ................................. 10 3.3 Results Obtained with the
   Recommended Reference Chemicals in Two Standard Tests for Basal
   Cytotoxicity with Human and Rodent Cells
   ....................................... 12 4.0 Recommended Basal
   Cytotoxicity Tests: BALB/C 3T3 And Normal Human Keratinocyte (NHK)
   Neutral Red Uptake (NRU) Tests
   ...............................................15 4.1 Validation Status
   of the 3T3 NRU Test
   .......................................................................
   ............... 15 4.2 Reliability of the 3T3 NRU Test
   .......................................................................
   .......................... 15 4.3 Validation Status of the NHK NRU Test
   .......................................................................
   ............. 18 4.4 Reliability of the NHK NRU
   Test...................................................................
   ............................ 19 5.0 Conclusion
   .......................................................................
   ...............................................................19
   Acknowledgement........................................................
   .......................................................................
   . 19 6.0 References
   .......................................................................
   ................................................................21
   Appendices
   .......................................................................
   .......................................................................
   .... A. Registry Of Cytotoxicity
   .......................................................................
   .................................... A-1 B. List of Test Protocols for
   Basal Cytotoxicity, European Centre for the Validation Of Alternative
   Methods (ECVAM) Scientific Information System (SIS) .............. B-1
   iii Table of Contents C. Standard Operating Procedure (SOP) for the
   BALB/c 3T3 Neutral Red Uptake Cytotoxicity Test - A Test for Basal
   Cytotoxicity........................................................
   C-1 1.0 Standard Operating Procedure (SOP) for the BALB/c 3T3 Neutral
   Red Uptake Cytotoxicity Test - A Test for Basal
   Cytotoxicity........................................ C-3 1.1 Background
   and
   Introduction...........................................................
   ............................ C-3 1.2
   Rationale..............................................................
   ......................................................... C-3 1.3 Basic
   Procedure..............................................................
   .............................................. C-3 1.4 Test
   Limitations............................................................
   ................................................ C-4 1.5 Material
   .......................................................................
   ................................................. C-4 1.6
   Methods................................................................
   ........................................................ C-6 1.7 Data
   Analysis
   .......................................................................
   ...................................... C-10 1.8 Prediction
   Model..................................................................
   ...................................... C-11 1.9 References
   .......................................................................
   ........................................... C-11 D. Standard Operating
   Procedure (SOP) for the Normal Human Keratinocyte Neutral Red Uptake
   Cytotoxicity Test - A Test for Basal Cytotoxicity
   ................................... D-1 1.0 Standard Operating
   Procedure (SOP) for the BALB/c 3T3 Neutral Red Uptake Cytotoxicity Test
   - A Test for Basal Cytotoxicity
   ............................................... D-3 1.1 Background and
   Introduction...........................................................
   ............................ D-3 1.2
   Rationale..............................................................
   ......................................................... D-3 1.3 Basic
   Procedure..............................................................
   .............................................. D-3 1.4 Test
   Limitations............................................................
   ................................................ D-3 1.5 Material
   .......................................................................
   ................................................. D-4 1.6
   Methods................................................................
   ........................................................ D-6 1.7 Data
   Analysis
   .......................................................................
   ........................................ D-9 1.8 Prediction
   Model..................................................................
   ...................................... D-10 1.9 References
   .......................................................................
   ........................................... D-10 E. 96-Well Plate
   Configuration
   .......................................................................
   ...............................E-1 F. Decimal Geometric Concentration
   Series
   .......................................................................
   ...........F-1 G. Standard Test Reporting
   Template...............................................................
   ............................. G-1 iv Table of Contents List of Tables
   1. Recommended reference chemicals for evaluating a cytotoxicity test
   for use with the RC prediction model
   .......................................................................
   ................11 2. Interlaboratory reproducibility of the 3T3 NRU
   cytotoxicity test determined according to ISO 5725 in 12 laboratories
   for 29 chemicals .........................................15 List of
   Figures 1. Registry of Cytotoxicity Regression Between Cytotoxicity
   (IC50x) and Rodent Acute Oral LD50 Values for 347
   Chemicals..............................................................
   .....3 2. Procedure for Evaluating a Cytotoxicity Test for Tiered In
   Vitro/In Vivo Testing for Acute Oral Toxicity Testing (Slightly
   Modified after Spielmann et. al.,
   1999)..................................................................
   ..........10 3. Regression Obtained by Testing the Recommended
   Reference Chemicals from the RC with Human Keratinocytes in the NHK NRU
   Cytotoxicity Test
   .......................................................................
   ...................................13 4. Regression Obtained by Testing
   the Recommended Reference Chemicals from the RC with Mouse Fibroblasts
   in the BALB/c 3T3 NRU Cytotoxicity
   Test...................................................................
   ..........................................13 5. Interlaboratory
   Comparability of the 3T3 NRU Cytotoxicity Test for 147 Test Chemicals
   in 2 Different Laboratories per
   Chemical..................................................17 List of
   Tables List of Figures List of Acronyms/Abbreviations Workshop Breakout
   Groups Acknowledgements Preface Executive Summary 1.0 INTRODUCTION v
   Table of Contents 1.1 Purpose and Scope of this Guidance Document 1.2
   The Correlation Between Basal Cytotoxicity and Acute Lethality 1.3 In
   Vitro Determination of Starting Dose for In Vivo Tests 1.4
   Determination of In Vitro Test Performance Characteristics 2.0 ELEMENTS
   OF A STANDARD TEST FOR BASAL CYTOTOXICITY 2.1 Selection of Cell Lines /
   Cells 2.2 Recommended Measurement Endpoints for Basal Cytotoxicity 2.3
   Recommendations for Cytotoxicity Test Protocols 3.0 PROCEDURE FOR
   QUALIFYING A CYTOTOXICITY TEST FOR USE WITH THE REGISTRY OF
   CYTOTOXICITY PREDICTION MODEL 3.1 Procedure to Determine Whether a
   Candidate Cytotoxicity Test Can Use the Registry of Cytotoxicity
   Prediction Model 3.2 Recommended Reference Chemicals from the RC for
   Test Qualification 3.3 Results Obtained with the Recommended Reference
   Chemicals in Two Standard Tests for Basal Cytotoxicity with Human and
   Rodent Cells 4.0 Recommended basal cytotoxicity TESTs: BALB/C 3T3 and
   Normal human keratinocyte (NHK) NEUTRAL RED UPTAKE (NRU) TESTs 4.1
   Validation Status of the 3T3-NRU Test 4.2 Reliability of the 3T3-NRU
   Test 4.3 Validation Status of the NHK-NRU Test 4.4 Reliability of the
   NHK-NRU Test 5.0 CONCLUSION ACKNOWLEDGEMENT 6.0 REFERENCES Appendices
   A. Registry Of Cytotoxicity B. List Of Test Protocols For Basal
   Cytotoxicity, European Centre For The Validation Of Alternative Methods
   (Ecvam) Scientific Information System (Sis) C. Standard Operating
   Procedure (Sop) For The Balb/C 3t3 Neutral Red Uptake Cytotoxicity Test
   - A Test For Basal Cytotoxicity 1.0 STANDARD OPERATING PROCEDURE (SOP)
   FOR THE BALB/C 3T3 NEUTRAL RED UPTAKE CYTOTOXICITY TEST - A TEST FOR
   BASAL CYTOTOXICITY 1.1 Background and Introduction 1.2 Rationale 1.3
   Basic Procedure 1.4 Test Limitations 1.5 Material 1.6 Methods 1.7 Data
   Analysis 1.8 Prediction Model 1.9 References vi List of
   Acronyms/Abbreviations ATC Acute Toxic Class ATCC American Type Culture
   Collection BALB/c Inbred strain of mouse BgVV Federal Institute for
   Health Protection of Consumers and Veterinary Medicine (Germany) BMFT
   Ministry of Research and Technology (Germany) BSS Balanced Saline
   Solution b.w. Body weight CAS Chemical Abstract Service CHO Chinese
   hamster ovary cell line (epithelial) CFR Code of Federal Regulations
   CMF-HBSS Calcium/Magnesium-Free Hanks' Balanced Salt (Saline) Solution
   COLIPA The European Cosmetic, Toiletry and Perfumery Industry CS Calf
   serum (bovine) CTFA The Cosmetic, Toiletry, and Fragrance Association
   (USA) CTLU Cytotoxicology Laboratory, Uppsala DMEM Dulbecco's
   Modification of Eagle's Medium without L-Glutamine DMSO Dimethyl
   Sulfoxide ECACC European Collection of Cell Cultures EC/HO European
   Commission/British Home Office ECVAM European Centre for the Validation
   of Alternative Methods EDTA Ethylenediaminetetraacetic Acid EPA
   Environmental Protection Agency ETOH Ethanol EZ4U Non-radioactive cell
   proliferation and cytotoxicity assay (Biomedica Gruppe) FBS Fetal
   Bovine Serum FDP Fixed-Dose Procedure FG Empirical linear-shaped
   prediction interval FL Fluorescein Leakage FRAME Fund for the
   Replacement of Animals in Medical Experiments GLP Good Laboratory
   Practice Regulations h Hour(s) HBSS Hanks' Balanced Salt (Saline)
   Solution HEL-30 Murine keratinocyte cell line Hepa-1 Mouse hepatoma
   cell line (epithelial) HEPES
   N-2-Hydroxyethylpiperazine-N'-2-ethanesulfonic acid HET-CAM Hen's Egg
   Test-Chorioallantoic Membrane HTD Highest tolerated dose IC50
   Inhibitory concentration estimated to affect endpoint in question by
   50% ICCVAM Interagency Coordinating Committee on the Validation of
   Alternative Methods ICH International Congress for Harmonization IIVS
   Institute for In Vitro Sciences INVITTOX ECVAM database ISO 5725 A
   program for analysis and reporting of proficiency tests and method
   evaluation studies vii List of Acronyms/Abbreviations ISO International
   Standards Organization KB Kenacid Blue KGM Keratinocyte Growth Medium
   L929 Mouse fibrosarcoma cell line (fibroblast) LD50 Dose producing
   lethality in 50% of the animals LDH Lactate Dehydrogenase MDCK Madin
   Darby canine kidney cells MEIC Multicentre Evaluation of In Vitro
   Cytotoxicity MEMO MEIC Monographs, CTLU MIT-24 Metabolic Inhibition
   Test MSDS Material Safety Data Sheet MTS
   3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
   (4-sulfophenyl)-2H-tetrazolium MTT
   3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide NBCS
   New-born Calf Serum (bovine) NICEATM NTP Interagency Center for the
   Evaluation of Alternative Toxicological Methods NIEHS National
   Institute of Environmental Health Sciences/NIH NIH National Institutes
   of Health/DHHS NIOSH National Institute for Occupational Safety and
   Health NHEK Normal Human Epidermal Keratinocytes NHK Normal Human
   Keratinocytes NR Neutral Red dye NR50 Mean concentration of test
   substance reducing viability of cells to 50% of the viability of
   controls NRU50 The concentration of the test article which inhibits the
   uptake of neutral red by 50% NRR Neutral Red Release NRU Neutral Red
   Uptake NTP National Toxicology Program OD540 Optical density at 540nm
   OECD Organization for Economic Cooperation and Development PBS
   Phosphate Buffered Saline PC Positive Control PHOTO-32 Software for
   concentration response analysis from 96-well plates PT Phototoxicity
   Test RC Registry of Cytotoxicity/ZEBET RTECS Registry of Toxic Effects
   of Chemical Substances SIS ECVAM Scientific Information System SLS
   Sodium Lauryl Sulfate SOP Standard Operating Procedures TG 420 Test
   Guideline 420 (Acute Oral Toxicity - Fixed Dose Method) [OECD] TG 423
   Test Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
   [OECD] TG 425 Test Guideline 425 (Acute Oral Toxicity: Up-and-Down
   Procedure) [OECD] viii List of Acronyms/Abbreviations TNS Trypsin
   Neutralizing Solution UDP Up-and-Down Procedure V79 Chinese hamster
   lung fibroblast cell line VC Vehicle Control XTT Sodium
   3,3-{1-[(phenylamino)carbonyl]-3,4-tetrazolium}-bis(4-methoxy-6-
   nitro)benzene sulfonic acid hydrate ZEBET German Centre for the
   Documentation and Validation of Alternative Methods (at BgVV) 3Rs
   Refinement, Reduction, and Replacement (of Animal Use) 3T3 BALB/c mouse
   fibroblast cells 3T3 A31 BALB/c mouse fibroblast cells  clone A31 ix
   List of Acronyms/Abbreviations x Acknowledgements Drs. Fentem, Curren,
   and Liebsch are acknowledged for their significant contributions to the
   guidance document. They along with the following scientists were
   invited to serve on the Breakout Group 1 panel for the International
   Workshop on In Vitro Methods for Assessing Acute Toxicology, October
   17-20, 2000. Workshop Breakout Group 1 In Vitro Screening Methods for
   Assessing Acute Toxicity Julia Fentem, Ph.D. (Co-Chair); (Co-Author)
   Alan Goldberg, Ph.D. Unilever Research Johns Hopkins University Center
   for Alternatives Shambrook Bedforshire, United Kingdom to Animal
   Testing Baltimore, MD Charles Tyson, Ph.D. (Co-Chair) SRI International
   A. Wallace Hayes , Ph.D., D.A.B.T., D.A.T.S. Menlo Park, CA The
   Gillette Company Boston, MA Robert Combes , Ph.D. Fund for the
   Replacement of Animals in Medical Manfred Liebsch , Ph.D. (Co-Author)
   Experiments (FRAME) German Centre for the Documentation and Nottingham,
   United Kingdom Validation of Alternative Methods (at BgVV) (ZEBET)
   Rodger Curren , Ph.D. (Co-Author) Berlin, Germany Institute for In
   Vitro Sciences, Inc. Gaithersburg, MD Lennart Romert , Ph.D. Swedish
   National Chemicals Inspectorate Elke Genschow, Ph.D. Solna, Sweden
   German Centre for the Documentation and Validation of Alternative
   Methods (at BgVV) Noriho Tanaka, Ph.D. (ZEBET) Hatano Research
   Institute Berlin, Germany Kanagawa, Japan ICCVAM Agency Participants
   Kailash Gupta , D.V.M., Ph.D. Philip Sayre , Ph.D. U.S. CPSC, Bethesda,
   MD U.S. EPA/OPPT, Washington, D.C. Kenneth Hastings , Ph.D. Leonard
   Schechtman , Ph.D. U.S. FDA/CDER, Rockville, MD U.S. FDA/CDER,
   Rockville, MD Richard N. Hill, M.D., Ph.D. Suhair Shallal, Ph.D. U.S.
   EPA/OPPT, Washington, D.C. U.S. EPA/OPP/HED, Arlington, VA Abdullah
   Khasawinah, Ph.D. William S. Stokes , D.V.M., D.A.C.L.A.M. U.S.
   EPA/OPP/HED, Arlington, VA NIEHS, Research Triangle Park, NC Elizabeth
   Margosches , Ph.D. U.S. EPA/OPPT/OPPTS, Washington, D.C. xi
   Acknowledgements ICCVAM Organizing Committee for the International
   Workshop on In Vitro Methods for Assessing Acute Systemic Toxicity
   Consumer Product Safety Commission Ronald Brown, Ph.D. (CPSC) Thomas
   Collins, Ph.D. Kailash Gupta, D.V.M., Ph.D. Peter Goering, Ph.D.
   Stephen Hundley, Ph.D. Department of Defense (DOD) John Frazier, Ph.D.,
   (Organizing Committee co- National Institute of Environmental Health
   chair) Sciences (NIEHS) Department of Transportation (DOT) Jerrold
   Heindel, Ph.D. George Cushmac, Ph.D. William Stokes, D.V.M. (ICCVAM
   Co-Chair) Errol Zeiger, Ph.D., J.D. Environmental Protection Agency
   (EPA) Richard Hill, M.D., Ph.D. (ICCVAM Co-Chair) National Institute
   for Occupational Safety Angela Auletta, Ph.D. and Health (NIOSH)
   Elizabeth Margosches, Ph.D. Kenneth Weber, Ph.D. Karen Hamernik, Ph.D.
   Philip Sayre, Ph.D. (Organizing Committee co- National Library of
   Medicine (NLM) chair) Vera Hudson, M.S.L.S. Maurice Zeeman, Ph.D.
   Occupational Safety and Health Food and Drug Administration (FDA)
   Administration (OSHA) Leonard Schechtman, Ph.D. Surender Ahir, Ph.D.
   Melvin Stratmeyer, Ph.D. National Toxicology Program (NTP) Interagency
   Center for the Evaluation of Alternative Toxicological Methods
   (NICEATM) Integrated Laboratory Systems (ILS), Inc. National Institute
   of Environmental Health Bradley Blackard, M.S.P.H. Sciences (NIEHS) Sue
   Brenzel Loretta Frye Ashlee Duncan, M.S. Debbie McCarley Thomas
   Goldworthy, Ph.D. William S. Stokes, D.V.M., D.A.C.L.A.M. Christina
   Inhof, M.S.P.H. (Director) Linda Litchfield Barry Margolin, Ph.D. Judy
   Strickland, Ph.D., D.A.B.T. Michael Paris Barbara Shane, Ph.D.,
   D.A.B.T. Raymond Tice, Ph.D. xii Acknowledgements Interagency
   Coordinating Committee on the Validation of Alternative Methods
   (ICCVAM) Agency for Toxic Substances and Disease Abby C. Jacobs, Ph.D.
   Registry (ATSDR) Center for Devices and Radiological Health *William
   Cibulas, Ph.D. +Mel E. Stratmeyer, Ph.D. Raju G. Kammula, D.V.M.,
   Ph.D., D.A.B.T. Consumer Product Safety Commission (CPSC) Center for
   Biologics Evaluation and *Marilyn L. Wind, Ph.D. Research Susan Aitken,
   Ph.D. +Patrick G. Swann Kailash C. Gupta, D.V.M., Ph.D. Center for Food
   Safety and Nutrition +David G. Hattan, Ph.D. Department of Defense
   (DOD) Victor P. Frattali *Harry Salem, Ph.D., U.S. Army Edgewood Center
   for Veterinary Medicine Chemical Biological Center +Devaraya Jagannath,
   Ph.D. John M. Frazier, Ph.D., U.S. Air Force, Wright- Louis T.
   Mulligan, D.V.M. Patterson AFB National Center for Toxicological
   Research +William T. Allaben, Ph.D. Department of Energy (DOE) Office
   of Regulatory Affairs *Marvin Frazier, Ph.D. +Atin Datta, Ph.D.
   Department of Interior (DOI) National Cancer Institute (NCI) *Barnett
   A. Rattner, Ph.D. *David Longfellow, Ph.D. Yung-Pin Liu, Ph.D.
   Department of Transportation (DOT) *James K. O'Steen National Institute
   of Environmental Health George Cushmac, Ph.D. Sciences (NIEHS) *William
   S. Stokes, D.V.M., D.A.C.L.A.M. Environmental Protection Agency (EPA)
   (Co-Chair) *Richard N. Hill, M.D., Ph.D. (Co-Chair) John R. Bucher,
   Ph.D., D.A.B.T. Office of Pollution Prevention and Toxics Rajendra S.
   Chhabra, Ph.D., D.A.B.T +Angela Auletta, Ph.D Philip Sayre, Ph.D.
   National Institute for Occupational Safety and Office of Pesticides
   Programs Health (NIOSH) +Karen Hamernik, Ph.D. *Doug Sharpnack, D.V.M.,
   D.A.C.V.P. Amy Rispin, Ph.D. +Paul Nicolaysen, V.M.D. Office of
   Research and Development +Harold Zenick, Ph.D. National Institutes of
   Health (NIH) Suzanne McMaster *Margaret D. Snyder, Ph.D. OECD Test
   Guidelines Program Maurice Zeeman, Ph.D. National Library of Medicine
   (NLM) *Vera Hudson, M.S.L.S. Food and Drug Administration (FDA)
   *Leonard M. Schechtman, Ph.D. Occupational Safety and Health Suzanne C.
   Fitzpatrick, Ph.D., D.A.B.T. Administration (OSHA) *Surender Ahir,
   Ph.D. Center for Drug Evaluation and Research +Joseph DeGeorge, Ph.D. *
   Principal Agency Representatives Joseph F. Contrera, Ph.D. + Principal
   Program Representatives 6/01 xiii Acknowledgements xiv Preface Acute
   systemic toxicity testing is conducted to cytotoxicity methods, and
   recommending whether determine the relative health hazard of chemicals
   and how these methods might be used to reduce and various products.
   Substances found to cause and refine animal use for acute toxicity
   testing. lethality in animals at or below prescribed doses The Group
   concluded that in vitro cytotoxicity are labeled to identify their
   hazard potential. data could be useful in estimating starting doses
   While acute toxicity testing is currently conducted for in vivo acute
   toxicity testing, which will using animals, studies published in recent
   years reduce the number of animals required for such have shown a
   correlation between in vitro and in determinations. Their conclusions
   were based on vivo acute toxicity. These studies suggest that in
   several studies but primarily those by Drs. Horst vitro methods may be
   helpful in predicting in vivo Spielmann and Willi Halle, and their
   colleagues at acute toxicity. the German Centre for the Documentation
   and Evaluation of Alternatives to Testing in Animals. An International
   Workshop on In Vitro Methods Halle compiled a Registry of Cytotoxicity
   for Assessing Acute Systemic Toxicity was containing in vivo acute
   toxicity data and in vitro convened on October 17-20, 2000, to review
   the cytotoxicity data for 347 chemicals. These data validation status
   of available in vitro methods for were used to construct a regression
   model to predicting acute toxicity, and to develop estimate LD50 values
   from cytotoxicity data. recommendations for future research and They
   subsequently proposed that using these development efforts that might
   further enhance estimates as starting doses for in vivo acute the use
   of in vitro assessments of acute systemic toxicity studies such as the
   Up-and-Down toxicity. The Workshop was organized by the Procedure or
   the Acute Toxic Class method could Interagency Coordinating Committee
   on the reduce the number of animals used by as much as Validation of
   Alternative Methods (ICCVAM) 30 percent. In addition, the Group
   recommended and the National Toxicology Program (NTP) that this
   guidance document be prepared to Interagency Center for the Evaluation
   of provide practical guidance on how to generate and Alternative
   Toxicological Methods (NICEATM). use basal cytotoxicity data to predict
   starting The U.S. Environmental Protection Agency (U.S. doses for in
   vivo acute toxicity assays. Drs. EPA), the NTP, and the National
   Institute of Manfred Liebsch, Rodger Curren, and Julia Environmental
   Health Sciences (NIEHS Fentem volunteered to draft this document and
   sponsored the workshop. Breakout Groups, after the Workshop they worked
   with NICEATM comprised of invited scientific experts and to develop it.
   This guidance document has been ICCVAM agency scientists, developed
   reviewed by ICCVAM, the ICCVAM Workshop conclusions and recommendations
   for four topics: Organizing Committee, and those participating in the
   Breakout Group on In Vitro Screening * In Vitro Screening Methods for
   Assessing Methods. Acute Toxicity; * In Vitro Methods for Toxicokinetic
   The workshop results have been published as the Determinations; Report
   on the International Workshop on In Vitro * In Vitro Methods for
   Predicting Organ Methods for Assessing Acute Systemic Toxicity Specific
   Toxicity; and (NIH Publication No. 01-4499). The Organizing * Chemical
   Data Sets for Validation of In Vitro Committee and ICCVAM developed
   test Acute Toxicity Test Methods. recommendations to forward with these
   publications to Federal agencies for their The Breakout Group that
   addressed the first topic, consideration in accordance with Public Law
   106- "In Vitro Screening Methods," was charged with 545. The ICCVAM
   recommendations are evaluating the current validation status of basal
   provided in the Workshop Report. Both xv Preface publications are
   available at the ICCVAM/NICEATM website (http://iccvam.niehs.nih.gov),
   or a copy may be requested from NICEATM at P.O. Box 12233, MD EC-17,
   Research Triangle Park, NC 27709 (mail), 919-541-3398 (phone),
   919-541-0947 (fax), or NICEATM@niehs.nih.gov (email). On behalf of the
   ICCVAM, we gratefully acknowledge the efforts of the Breakout Group on
   In Vitro Screening Methods for their comprehensive evaluation of
   existing data and methods that served as the impetus for this guidance
   document. We extend our sincere appreciation to the contributing
   authors, Drs. Manfred Liebsch, Rodger Curren, and Julia Fentem, for
   their considerable efforts and contributions to this document. The
   efforts of the NICEATM staff in coordinating the preparation and
   publication of the document are acknowledged and appreciated,
   particularly those of Dr. Judy Strickland and Mr. Michael Paris, who
   worked diligently with the authors to produce the final version.
   William S. Stokes, D.V.M. Co-Chair, ICCVAM NIEHS Richard N. Hill, M.D.,
   Ph.D. Co-Chair, ICCVAM U. S. EPA xvi Using In Vitro Data to Estimate In
   Vivo Starting Doses for Acute Toxicity 1.0 INTRODUCTION Appendix B
   contains a list of test protocols for basal cytotoxicity from the
   Scientific Information 1.1 Purpose and Scope of this Guidance System
   (SIS) of the European Centre for the Document Validation of Alternative
   Methods (ECVAM). Appendices C-G provide detailed stand-alone This
   guidance document describes how to use in protocols for BALB/c 3T3 and
   NHK NRU assays, vitro cytotoxicity tests to estimate starting doses
   additional guidance for implementing the for acute oral lethality
   assays. Development of protocols, and a standard template for data this
   document was recommended by participants collection. in the
   International Workshop on In Vitro Methods for Assessing Acute Systemic
   Toxicity, 1.2 The Correlation between Basal held October 17-20, 2000,
   in Arlington, VA, Cytotoxicity and Acute Lethality U.S.A. The
   Interagency Coordinating Committee on the Validation of Alternative
   Methods Acute oral toxicity testing is typically the first step
   (ICCVAM) and the National Toxicology Program in identifying and
   characterizing the hazards Interagency Center for the Evaluation of
   associated with a particular chemical. Alternative Toxicological
   Methods (NICEATM) Information derived from acute toxicity tests in
   convened the workshop to evaluate the validation laboratory animals
   (mainly rodents) is used for status of available in vitro methods for
   assessing several purposes, including: (a) hazard acute toxicity. A
   workshop breakout group classification and labeling of chemicals in
   reviewed the use of in vitro screening methods to accordance with
   national and international estimate acute in vivo toxicity (i.e., LD50
   values) regulations (e.g., 49 Code of Federal Regulations and
   recommended the development of this [CFR] 173; 16 CFR 1500; 29 CFR
   1910; 40 CFR guidance document which was written by three of 156;
   Organisation for Economic Co-operation and its members. Development
   [OECD], 1998a); (b) risk assessments pertaining to the acceptability of
   This introduction summarizes background acute exposures in the
   workplace, at home, and information about the correlation between in
   vitro upon accidental release; (c) clinical diagnosis, cytotoxicity and
   acute lethality, explains the treatment and prognosis of acute human
   poisoning purpose of using in vitro cytotoxicity assays to cases; and
   (d) design (e.g., dose-setting, predict starting doses for in vivo
   acute lethality identification of potential target organs) of longer-
   assays, and describes a general approach for term (e.g., 28-day)
   toxicity studies. Historically, evaluating in vitro test performance.
   Chapter 2 lethality estimated by the LD50 test has been a describes the
   basic elements of in vitro assays for primary toxicological endpoint in
   acute toxicity basal cytotoxicity and describes what tests, although
   more detailed toxicological investigators should consider before
   applying the information is sometimes collected. More results of these
   assays to their own situations. recently, the conventional test
   procedure has been Chapter 3 describes the use of the Registry of
   modified in various ways to refine and reduce Cytotoxicity (RC)
   prediction model to evaluate a animal use (OECD, 1992, 1996, 1998b).
   Aiding candidate cytotoxicity assay. The RC prediction the acceptance
   of these alternative methods has model is a regression analysis of LD50
   values (the been the recognition that the LD50 is not a median lethal
   dose, i.e., the dose that produces biological constant, but is
   influenced by many lethality in 50% of the animals tested) and in vitro
   factors (Klaassen and Eaton, 1991). For most cytotoxicity IC50 values
   (i.e., concentration at purposes, the LD50 only needs to be
   characterized which cell viability is inhibited by 50%) for 347 "within
   an order of magnitude range," according chemicals. Chapter 4 describes
   two candidate to Klaassen and Eaton (1991). tests recommended for use
   with this method: neutral red uptake (NRU) assays using the mouse The
   use of cell cultures in vitro as alternatives to fibroblast cell line
   BALB/c 3T3 and normal predict acute lethality in vivo has been under
   study human keratinocytes (NHK). Appendix A for almost 50 years
   (Pomerat and Leake, 1954; contains the RC data in spreadsheet format.
   Eagle and Foley, 1956; Smith et al., 1963). 1 Using In Vitro Data to
   Estimate In Vivo Starting Doses for Acute Toxicity Numerous
   demonstrations of strong correlations between cytotoxicity in vitro and
   animal lethality in vivo exist. (For reviews see Phillips et al., 1990,
   and Garle et al., 1994). Recently, several major international in vitro
   initiatives have been directed toward reducing the use of laboratory
   animals for acute toxicity testing (Curren et al., 1998; Ekwall et al.,
   2000; Ohno et al., 1998a, 1998b, 1998c; Seibert et al., 1996; Spielmann
   et al., 1999). The status of these initiatives was reviewed at the
   International Workshop on In Vitro Methods for Assessing Acute Systemic
   Toxicity, jointly sponsored by the National Institute of Environmental
   Health Sciences (NIEHS), the National Toxicology Program (NTP), and the
   U.S. Environmental Protection Agency (U.S. EPA). Conclusions and
   recommendations from the workshop are published in the Report of the
   International Workshop on In Vitro Methods for Assessing Acute Systemic
   Toxicity (NIEHS, 2001). The RC has made a major contribution to the
   knowledge of the correlation between in vitro cytotoxicity and in vivo
   lethality (Halle and Spielmann, 1992; Halle, 1998). The most recent RC
   compilation (Halle, 1998) contains in vitro cytotoxicity information
   (1,912 single IC50 values averaged for each of 347 chemicals [i.e., one
   IC50x value/chemical from multiple reports in the literature]) paired
   with 347 in vivo acute oral LD50 values (mmol/kg) for rats (282 values)
   or mice (65 values) from the National Institute for Occupational Safety
   and Health (NIOSH) Registry of Toxic Effects of Chemical Substances
   (RTECS). (See Appendix A for the RC data.) Criteria for data to be
   included in the RC database are fully described by Halle (1998) and
   briefly described by Spielmann et al. (1999). The combination of rat
   and mouse data was justified, since it yielded a regression that was
   not significantly different from those obtained with either rat data or
   mouse data alone. The RC data clearly demonstrate a strong relationship
   between in vitro cytotoxicity and acute lethality in rodents (Figure
   1). 2 Using In Vitro Data to Estimate In Vivo Starting Doses for Acute
   Toxicity Regression between cytotoxity (IC 50x) and acute oral LD 50
   values 1000 100 10 1 0.1 LD50 (mmol/kg) 0.01 0.001 0.0001 0.00001 0.001
   0.1 10 1000 IC50x (mmol/l) Figure 1. Registry of Cytotoxicity
   regression between cytotoxicity (IC 50x) and rodent acute oral LD50
   values for 347 chemicals. The heavy line shows the fit of the data to a
   linear regression model, log (LD50) = 0.435 x log (IC50x) + 0.625;
   r=0.67. The other lines show the empirical FG = Â± log 5 acceptance
   interval for the prediction model (Spielmann et al., 1999), which is
   based on the anticipated precision of LD50 values from rodent studies
   Halle (1998). 1.3 In Vitro Determination of Starting Dose specifically
   a value in mmol/kg. This value must for In Vivo Tests first be
   converted to a weight measurement expression, such as mg/kg, before
   using Spielmann et al. (1999) have proposed  as an conventional LD50
   dosing calculations. Using this initial step  that the relationship
   found with the estimate should make the conduct of in vivo RC
   regression be used with in vitro data to predict assays much more
   efficient and result in savings starting doses for subsequent in vivo
   acute both in the number of animals and in the amount lethality assays.
   They suggest that before of time required to obtain the final results.
   The initiating any in vivo lethality assay for a workshop report
   (NIEHS, 2001) includes a chemical, an in vitro cytotoxicity assay
   should be discussion of the potential number of animals conducted to
   estimate the LD50 for that chemical. saved, based on several currently
   available in vivo The LD50 predicted from the RC regression protocols,
   e.g., protocols that use new sequential equation should then be used to
   choose the most dosing methods such as the Acute Toxic Class
   appropriate starting dose for the in vivo assay. method (ATC, OECD TG
   423; OECD, 1996) and The LD50 estimate from the RC regression is the
   Up-and-Down Procedure (UDP, OECD TG based on molar amounts of the
   chemical, 425; OECD, 1998b). In these tests, using the 3 Using In Vitro
   Data to Estimate In Vivo Starting Doses for Acute Toxicity fewest
   animals possible depends upon the correct choice of starting dose
   since, on average, the number of consecutive dosing steps is minimal if
   the starting dose is close to the true toxicity class (ATC) or to the
   true LD50 (UDP). 1.4 Determination of In Vitro Test Performance
   Characteristics Before the results obtained with any in vitro
   cytotoxicity test are used with the RC regression to generate an
   expected LD50 value, the performance characteristics of the new method
   should be determined and compared with those of the RC information as
   discussed in Section 3.1. Section 3.2 suggests a set of reference
   chemicals that should be tested with the candidate in vitro
   cytotoxicity method. The resultant regression line should then be
   compared with that of the current RC regression line. If the line falls
   within the + log 5 boundaries indicated in Figure 1, then the
   regression parameters of the RC may be used to predict the LD50
   starting dose. Section 3.3 describes experimental trials, using two
   different cell types, performed after the workshop with the set of
   recommended reference chemicals. These experimental trials are included
   as examples of how to determine test performance for any in vitro test
   for basal cytotoxicity and to confirm the applicability of the test for
   use with the RC regression. 4 Using In Vitro Data to Estimate In Vivo
   Starting Doses for Acute Toxicity 2.0 ELEMENTS OF A STANDARD TEST
   significant differences between the basal FOR BASAL CYTOTOXICITY
   cytotoxicity results obtained using permanent mammalian cell lines,
   primary human cells, or It is likely that many different in vitro
   cytotoxicity using the IC50X approach of Halle and Spielmann methods
   could be used to help select the in vivo (Halle, 1998; Spielmann et
   al., 1999; Halle and starting dose for an acute lethality assay. Two
   Spielmann, 1992). Thus, primary cells, as well as decades of experience
   indicate that in vitro basal many currently available mammalian cell
   lines cytotoxicity data determined in various primary could be used,
   provided they are of sufficient cells, as well as in various permanent
   non- quality to assure reproducibility over time. differentiated finite
   or transformed cell lines, However, rodent (i.e., rat or mouse) or
   human generally show comparable cytotoxic cells are expected to be most
   useful for this concentrations of the same xenobiotic, regardless
   approach. Established rodent cell lines are of the type of toxic
   endpoints investigated. The recommended because: 1) it is assumed that
   RC data, which consist of information from many rodent cells would give
   the best prediction of different in vitro methods that vary in both
   cell rodent acute lethality, and 2) the use of a standard type and
   cytotoxicity endpoint (i.e., specific cell type for this in vitro
   cytotoxicity technique protocol), indicated that exceptions to this
   "rule" will hasten the generation of a database that can were observed
   only for those chemicals (some be used to analyze the usefulness of
   this approach. insecticides, neurotropic chemicals, and chemicals There
   are also arguments for utilizing human cell requiring metabolic
   activation) that require lines to assess basal cytotoxicity. For
   example, an specific cell types to express their toxicity (Halle,
   analysis of the RC rodent acute lethality data 1998). Thus, a
   recommendation cannot be made relative to cytotoxicity data generated
   using for the "most relevant" or "most typical" in vitro human cell
   lines in the MEIC program showed test for basal cytotoxicity. that both
   were highly correlative (R2=0.90) (NIEHS, 2001). A long-term advantage
   of using Currently the ECVAM SIS lists 20 different test human cells is
   that the human cell cytotoxicity protocols for basal cytotoxicity.
   (Appendix B and data derived from this approach can be added to
   http://www.ivtip.org/protocols.html#basalcyto.) human toxicity
   databases to facilitate the Several in vitro tests listed in the SIS as
   "specific" development of methods that may later predict for a certain
   purpose, such as prediction of eye acute human lethality. and skin
   irritancy, in fact provide only basal cytotoxicity information. Of the
   rodent cell lines used for basal cytotoxicity, the mouse fibroblast
   cell line BALB/c 3T3 A31 is Nonetheless, since the responsiveness of
   all cell probably the most frequently used. Thus, a stable culture test
   systems to xenobiotics can be background of historical data exists,
   including influenced significantly by test design and culture data from
   controlled and blinded validation conditions, there is a consensus
   among in vitro studies (Gettings et al., 1991, 1992, 1994a, 1994b;
   toxicologists to give preference to protocols that Spielmann et al.,
   1991, 1993, 1996; Balls et al., are highly responsive. For example,
   while 1995; Brantom et al., 1997). Other rodent cell increasing
   exposure times (e.g., from 1 hour [h] lines that have been used in
   basal cytotoxicity up to 48 h) will usually increase the assays are
   described by Clemedson et al. (1996). responsiveness of the test, an
   increase in serum in the culture medium (e.g., from 5% up to 20%) Of
   the human cells used for basal cytotoxicity, will generally decrease
   the responsiveness of a NHK or fibroblasts are probably the cells most
   cytotoxicity test. frequently used with good results in validation
   studies (Willshaw et al., 1994; Sina et al., 1995; 2.1 Selection of
   Cell Lines / Cells Gettings et al., 1996; Harbell et al., 1997).
   Analyses performed before or during the Fish cell lines or invertebrate
   cell lines are not workshop (NIEHS, 2001) did not reveal recommended
   for determining basal cytotoxicity 5 Using In Vitro Data to Estimate In
   Vivo Starting Doses for Acute Toxicity (Ekwall et al., 1998). Although,
   according to the qualify new cytotoxicity protocols for use with the
   concept of basal cytotoxicity, they are expected to RC method for
   predicting starting doses for acute show failure of the same basic cell
   functions as lethality assays in vivo. mammalian cells would show at
   comparable chemical concentrations, it is not easy to create 2.2
   Recommended Measurement test designs that are highly responsive to
   Endpoints for Basal Cytotoxicity xenobiotics. For example, due to
   doubling times of up to several days, the responsive growth Many
   measurement endpoints for cytotoxicity are inhibition protocol cannot
   be used easily. well established and have been used to assess basal
   cytotoxicity. For inclusion of IC50 values in Highly differentiated
   cells may not give the best the RC, the following endpoints were
   accepted as prediction of acute lethality for the large variety of
   sufficiently characteristic of basal cytotoxicity chemicals likely to
   be tested for acute toxicity (Spielmann et al., 1999; Halle, 1998):
   (Ekwall et al., 1998). For example, to eliminate the possibility of
   metabolic activation or 1) Inhibition of cell proliferation:
   inactivation of chemicals, neither hepatocyte nor * Cell number
   hepatoma cytotoxicity data were included in the * Cell protein RC. This
   does not preclude the use of hepatocytes * DNA content, DNA synthesis
   in future studies, however, either to estimate * Colony formation
   cytotoxicity or to investigate the effect of metabolism or
   cell-specific toxicity (Seibert et al., 2) Cell viability - metabolic
   markers: 1996). Hepatocytes are essential to investigations * Metabolic
   inhibition test (MIT-24) of metabolism-mediated toxicity that will be *
   Mitochondrial reduction of tetrazolium salts required to meet the
   longer-term goal of replacing into insoluble dye (MTT test), in vivo
   acute lethality testing with in vitro or, more recently, into soluble
   dye (MTS methods (Seibert et al., 1996). test or XTT test [e.g.,
   "EZ4U"]). Whether rodent or human cells are used, they 3) Decreased
   cell viability - membrane markers: should be capable of active division
   (population * NRU into cell lysosomes doubling time of approximately 30
   h or less) so * Trypan Blue exclusion that chemicals that exert their
   toxicity primarily * Cell attachment, cell detachment during cell
   division will be adequately detected in these relatively short-term
   assays. As described in 4) Differentiation markers Section 2.3,
   chemical exposure should last at least * Functional differentiation
   within cell islets one full cell cycle. * Morphological differentiation
   within cell islets Finally, selection of a cell line always should be *
   Intracellular morphology made in the context of the intended
   cytotoxicity endpoint to be measured. For example, if NRU is Markers of
   the release of intracellular the intended measurement endpoint, the
   cells used components, such as the enzyme lactate must possess a
   significant amount of lysosomes to dehydrogenase (i.e., LDH release
   test), or of dye incorporate neutral red dye. Embryonic stem introduced
   into the cells previous to chemical cells, for example, do not contain
   the requisite exposure (e.g., fluorescein leakage [FL] test or
   organelles, and NRU cannot be used to determine Neutral Red Release
   [NRR] test) were not cytotoxicity in these cells. considered to be
   characteristic for basal cytotoxicity because they specifically detect
   Both the mouse and human cells mentioned above damage of the outer cell
   membrane and generally are easily obtainable from commercial sources.
   are associated with short-term chemical exposure. Cytotoxicity data
   from both the BALB/3T3 A31 A chemical that specifically damages only
   cell cell line and NHK cells are presented in Section membranes,
   however, will be detected correctly in 3.3 of this document as examples
   of how to one of the tests for basal cytotoxicity listed above. 6 Using
   In Vitro Data to Estimate In Vivo Starting Doses for Acute Toxicity
   reproducibility. Give 2.3 Recommendations for Cytotoxicity Test
   preference to endpoints that Protocols determine either cell
   proliferation or cell viability Since the RC was constructed with data
   from (e.g., NRU, MTT, XTT). many different in vitro protocols, a number
   of Simple endpoints such as total different in vitro cytotoxicity
   protocols might protein content are not produce correlations with in
   vivo acute lethality recommended, as they may similar to the
   correlation produced by the RC. It under-predict the toxicity of is
   strongly suggested, however, that any proposed certain test chemicals
   by in vitro protocol incorporate the following staining dead cells.
   conditions: (h) The protocol should be compatible with 96-well plates
   (a) Use a cell line (or primary and apparatus such as cells) that
   divides rapidly with spectrophotometers that allow a doubling times of
   less than 30 h quick and precise measurement under standard culture of
   the endpoint. conditions, preferably with (i) Complete a detailed
   normal serum types, e.g., calf concentration-response serum (CS),
   newborn calf experiment using a progression serum (NBCS), or serum-free
   factor that yields graded effects medium. between no effect and total
   (b) Use only cells in the cytotoxicity. Any desired exponential phase
   of growth. toxicity measure can be derived Never use cells immediately
   from a well-designed after thawing them from frozen
   concentration-response stock. Allow cells to grow 1-2 experiment.
   Experiments that passages before they are used in seek to detect only a
   marker the cytotoxicity test. concentration, such as the (c) The
   chemical exposure period highest tolerated dose or the should be at
   least the duration lowest cytotoxic dose, are of one cell cycle, i.e.,
   24  72 h characterized by a lack of (Riddell et al., 1986). information
   and a low level of (d) Initial seeding should be done accuracy. at a
   density that allows rapid growth throughout the exposure period. (e)
   Use appropriate positive and vehicle control materials for which
   cytotoxicity, or lack of cytotoxicity, has been well characterized by
   the performing laboratory. (f) Use solvents only at levels previously
   shown not to cause cytotoxicity to the cell system over the entire
   period of the assay. (g) Use a measurement endpoint that is well
   established and that has good interlaboratory 7 Using In Vitro Data to
   Estimate In Vivo Starting Doses for Acute Toxicity 8 Using In Vitro
   Data to Estimate In Vivo Starting Doses for Acute Toxicity 3.0
   PROCEDURE FOR QUALIFYING A 3.1 Procedure to Determine Whether a
   CYTOTOXICITY TEST FOR USE Candidate Cytotoxicity Test Can Use WITH THE
   REGISTRY OF the RC Prediction Model CYTOTOXICITY (RC) PREDICTION MODEL
   To determine whether predicted LD50 values from a basal cytotoxicity
   method can be used as starting Workshop participants agreed that tests
   of basal doses for routine testing of acute oral toxicity with
   cytotoxicity were sufficiently predictive for the the ATC or the UDP
   methods, Spielmann et al. rodent LD50 such that cytotoxicity tests
   could be (1999) suggested a procedure which is shown in used to predict
   a starting dose for an in vivo Figure 2. Ten to twenty reference
   chemicals are lethality assay (NIEHS, 2001). This section selected from
   the RC (Halle, 1998) and tested in a discusses how to proceed.
   Theoretically, any in standardized cytotoxicity test (Figure 2, Step
   1). vitro test capable of determining basal A promising candidate would
   be the BALB/c 3T3 cytotoxicity could be used to determine the best NRU
   test (see Appendix C for the Standard estimate of a starting dose for
   acute testing in the Operating Procedure [SOP]), which has been UDP
   (OECD, 1998b), the ATC method (OECD, highly reproducible in several
   validation studies 1996), or the Fixed Dose Procedure (FDP; TG
   (Gettings et al., 1991, 1992, 1994a, 1994b; 420, OECD, 1992). In
   addition, if the LD50 Spielmann et al., 1991, 1993, 1996; Balls et al.,
   predicted from cytotoxicity is high (i.e., 2,000 1995; Brantom et al.,
   1997). An alternative test, mg/kg b.w.), a range-finding study for the
   ATC or less frequently used, which has also yielded good FDP may not be
   necessary, as testing could be results in validation studies, is the
   NHK NRU initiated using the limit test of 2,000 or 5,000 assay
   (Willshaw et al., 1994; Sina et al., 1995; mg/kg. Gettings et al.,
   1996; Harbell et al., 1997). Before using a candidate in vitro
   cytotoxicity test To allow comparison of the regression obtained to
   predict starting doses, the correlation between with the candidate test
   (Figure 2, Step 2), selected the in vitro test and the in vivo test
   must be reference chemicals should cover the entire range established
   quantitatively. This can be achieved of cytotoxicity and be as close as
   possible to the either by (1) in vitro testing of a large number of RC
   regression line. (Section 3.2 presents a table chemicals with known
   LD50 values and deriving a with 11 reference chemicals from the RC and
   their regression formula based on the correlation corresponding LD50
   values.) The regression between in vivo and in vitro data, or by (2)
   testing equation from the candidate test is calculated by a smaller
   number of chemicals and applying linear regression (least square
   method) using the Halle's RC prediction model (i.e., regression
   candidate IC50 values and the corresponding LD50 formula), which is
   derived from the correlation of values from the RC (given in Table 1 in
   Section in vivo and in vitro data for 347 chemicals (Halle, 3.2). The
   resulting regression is then compared 1998; Spielmann et al., 1999). In
   the latter case, with the RC regression (Figure 2, Step 3). in vitro
   data for a small number of reference chemicals from the RC are compared
   with in vitro If the regression line obtained with the candidate data
   from the RC to determine the adequacy of the cytotoxicity test
   parallels the RC regression and is test method. within the + log 5
   interval, then the test is considered suitable to generate IC50 data to
   use Section 3.1 explains this procedure. Section 3.2 with the RC
   regression for estimating starting provides a set of 11 recommended
   reference doses (Figure 2, Step 4). The rationale for using chemicals
   from the RC. Section 3.3 presents the RC regression rather than the
   regression from experimental data from testing these 11 reference the
   candidate cytotoxicity test is that the RC chemicals in the NRU
   cytotoxicity assay with regression is based on data from 347 chemicals,
   both NHK cells and BALB/c 3T3 cells. while the candidate regression is
   based on data from only 10-20 chemicals. To predict an LD50 starting
   dose, the IC50 (in mmol/l) for the trial chemical is entered into the
   regression equation to 9 Using In Vitro Data to Estimate In Vivo
   Starting Doses for Acute Toxicity calculate an LD50 in mmol/kg b.w.
   Multiplying candidate cytotoxicity test to a higher or lower by the
   molecular weight of the trial chemical slope. (Note: This option was
   added post hoc transforms the mmol/kg b.w. value into mg/kg publication
   of Spielmann et al., 1999.) However, b.w. a more efficient approach is
   likely to be to use one of the recommended cell lines (Section 2.1) and
   If the regression from the candidate test shows a protocols (e.g.,
   Appendices C and D). These are significantly higher or lower slope than
   the RC expected to produce results similar to the RC data. regression,
   then it may be possible to adjust the Two examples are given in Section
   3.3. Step 1: Cytotoxicity test Test 10 - 20 reference chemicals (low -
   high cytotoxicity) taken from the RC, e.g. in the 3T3-Neutral Red
   Uptake test Step 2: Linear regression analysis Use IC50 values and RC
   LD50 values to calculate regression log (LD50) = a x log (IC50) +b Step
   3: Comparison of regressions Compare resulting regression with RC
   regression log (LD50) = 0.435 x log (IC50) + 0.625 Is regression
   parallel and within FG range ? Use recommended cells NO: and protocol
   to better tune test sensitivity YES Step 4: Use test to predict
   starting dose for UDP or ATC Figure 2. Procedure for evaluating a
   cytotoxicity test for tiered in vitro/in vivo testing for acute oral
   toxicity testing (slightly modified from Spielmann et al., 1999). 3.2
   Recommended Reference Chemicals from the RC for Test Qualification *
   Cytotoxicity range must cover 5 - 6 logs from low to high toxicity. To
   compare a regression obtained from a * Chemical data points
   (IC50x/LD50) candidate cytotoxicity test with the RC, 11 must be very
   close to the RC reference chemicals (Table 1) from Halle's RC
   regression line. (Halle, 1998) were selected using the following
   criteria: 10 Using In Vitro Data to Estimate In Vivo Starting Doses for
   Acute Toxicity * Chemicals must be available * Handling of chemicals
   must be internationally, preferably from acceptable with regard to one
   supplier. sufficient solubility, low * Available purity of chemicals
   volatility, and safe use (e.g., must be 95%. avoid the use of known
   carcinogens). Table 1. Recommended reference chemicals for evaluating a
   cytotoxicity test for use with the RC prediction model Chemical IC50x
   LD50 LD50 Molecular CAS Sigma- Possible hazards; Name (mmol/ (mmol/
   (mg/ Weight Number Aldrich Purity risk phrases from liter) kg b.w.) kg
   b.w.) (g) Puchase # MSDS Sodium 0.00093 0.19 49.8 298.0 7789-12-0 S9791
   99.5% Very toxic, corrosive, dichromate (VI) possible carcinogen.
   dihydrate Cadmium II 0.0064 0.48 88.0 183.3 10108-64-2 C2544 >99.0% May
   cause cancer. chloride Harmful if swallowed. Prolonged exposure through
   inhalation or skin contact may cause serious health damage.
   p-Phenylene- 0.05 0.74 80.0 108.16 106-50-3 P6001 N/A Toxic, irritant,
   diamine possible mutagen. DL-Propranolol 0.12 1.59 470.4 295.84
   3506-09-0 P0884 N/A Toxic. HCl Trichlorfon 0.27 1.75 450.5 257.44
   52-68-6 T5015 N/A Toxic by inhalation. May cause sensitization by skin
   contact. Ibuprofen 0.52 4.89 1008.9 206.31 15687-27-1 I4883 N/A Harmful
   if swallowed. Possible risk of harm to unborn child. Nalidixic acid 1.5
   5.81 1349.4 232.26 389-08-2 N8878 N/A Possible risk of harm to unborn
   child. May cause sensitization by inhalation, skin contact. Salicylic
   acid 3.38 6.45 890.9 138.13 69-72-7 S6271 >99.0% May cause harm to
   unborn child. Harmful if swallowed. Irritating to eyes, respiratory
   system, skin. Antipyrene 11.6 9.56 1799.7 188.25 60-80-0 A5882 N/A
   Irritant. Dimethyl 114 38.3 2800.1 73.11 68-12-2 D8654 >99.8% Irritant,
   teratogen. formamide Glycerol 624 137 12,691.1 92.11 56-81-5 G8773 >99%
   Irritating to eyes, skin. 11 Using In Vitro Data to Estimate In Vivo
   Starting Doses for Acute Toxicity 3.3 Results Obtained with the New NHK
   NRU regression: Recommended Reference Chemicals in log (LD50) = 0.498 x
   log (IC50) + 0.551 Two Standard Tests for Basal [R2 = 0.9356]
   Cytotoxicity with Human and Rodent Cells New 3T3 NRU regression: log
   (LD50) = 0.506 x log (IC50) + 0.475 The approach of using the RC
   regression (i.e., the [R2 = 0.9848] RC prediction model) to estimate an
   LD50 using data from a qualified cytotoxicity test was based As
   expected, due to selection of reference on experience with comparable
   data obtained with chemicals with data points close to the RC various
   basal cytotoxicity tests (provided they regression, the determination
   coefficients (R2) of followed the principles described previously). To
   the new NHK and 3T3 regressions are very high. convince even skeptical
   readers that cytotoxicity data for a small number of well selected
   reference In conclusion, by testing only 11 well selected chemicals
   would provide a candidate regression reference chemicals from the RC,
   both the NHK sufficiently comparable to the RC regression, the NRU and
   3T3 NRU tests yielded regression Institute for In Vitro Sciences (IIVS,
   equations very close to the regression equation of Gaithersburg, MD)
   subsequently tested the 11 the RC. Thus, both candidate cytotoxicity
   tests reference chemicals recommended in Section 3.2 met the acceptance
   criteria of a test for basal using two candidate NRU test protocols
   (see cytotoxicity defined by Spielmann et al. (1999). SOPs in
   Appendices C and D). The cells used in this exercise were NHK obtained
   commercially from Clonetics Corp (Walkersville, MD, USA) and mouse
   BALB/c 3T3 clone A31 cells. Each of the 11 reference chemicals was
   tested in three independent test trials with each of the two cell
   types. The outcomes of the experiments are shown in Figure 3 for the
   NHK and in Figure 4 for the BALB/c 3T3. Both figures depict the RC
   regression Â± log 5 interval (black lines) and the 11 reference
   chemicals (triangles). Other chemicals from the RC were omitted for
   clarity. The new IC50 values (means of the three trials) obtained with
   the NHK NRU test (Figure 3), or 3T3 NRU test (Figure 4) are shown
   (squares), as well as the new linear regression lines determined from
   these data (gray dashed line). The new regression lines obtained with
   NHK and 3T3 cells are within the Â± log 5 interval of the RC, and,
   though slightly steeper, are almost parallel to the RC regression
   function. Thus, intercepts and regression coefficients of the
   experimentally obtained new regressions do not differ significantly
   from the literature-based RC regression equation: RC regression: log
   (LD50) = 0.435 x log (IC50x) + 0.625 12 Using In Vitro Data to Estimate
   In Vivo Starting Doses for Acute Toxicity 1000.00000 Dimethylformamide
   100.00000 Salicylic acid Propranolol HCl Cadmium Chloride 10.00000
   Glycerol 1.00000 Antipyrine Nalidixic acid (mmol/kg) 0.10000 50
   Ibuprofen LD Trichlorfon p-Phenylenediamine 0.01000 Sodium Bichromate
   VI 0.00100 0.00010 0.00001 0.0001 0.001 0.01 0.1 1 10 100 1000 IC50x
   (mmol/l) Figure 3. Regression obtained by testing the recommended
   reference chemicals from the RC with human keratinocytes in the NHK NRU
   cytotoxicity test Figure shows the RC prediction regression (black bold
   line) Â± log 5 interval (black thin lines) and the 11 reference
   chemicals (triangles). The new IC50 /LD50 points obtained with the NHK
   NRU test are shown (black squares) with the new linear regression line
   determined from these data (gray dashed line). 1000.00000
   Dimethylformamide 100.00000 Salicylic acid Propranolol HCl Cadmium
   Chloride 10.00000 Glycerol 1.00000 Antipyrine Nalidixic acid (mmol/kg)
   0.10000 50 Ibuprofen LD Trichlorfon 0.01000 p-Phenylenediamine Sodium
   Bichromate VI 0.00100 0.00010 0.00001 0.0001 0.001 0.01 0.1 1 10 100
   1000 IC50x (mmol/l) Figure 4. Regression obtained by testing the
   recommended reference chemicals from the RC with mouse fibroblasts in
   the BALB/c 3T3 NRU cytotoxicity test. Figure shows the RC prediction
   regression (black bold line) Â± log 5 interval (black thin lines) and
   the 11 reference chemicals (triangles). The new IC50 /LD50 points
   obtained with the BALB/c 3T3 NRU test are shown (black squares) with
   the new linear regression line determined from these data (gray dashed
   line). 13 Using In Vitro Data to Estimate In Vivo Starting Doses for
   Acute Toxicity 14 Using In Vitro Data to Estimate In Vivo Starting
   Doses for Acute Toxicity 4.0 RECOMMENDED BASAL presented in Appendix
   C.) Five independent CYTOTOXICITY TESTS: BALB/C repeat tests were
   conducted per laboratory. Of 3T3 AND NORMAL HUMAN these 32 chemicals,
   three compounds [n-hexane, KERATINOCYTE (NHK) NEUTRAL aluminum
   hydroxide, and di-(2-ethyl- RED UPTAKE (NRU) TESTS hexyl)phthalate]
   showed unacceptably high inter- laboratory variability. For the other
   29 chemicals, 4.1 Validation Status of the 3T3 NRU Test interlaboratory
   variability was acceptable (Table 2). Interlaboratory reproducibility
   was assessed The BALB/c 3T3 NRU test is probably the with a standard
   procedure recommended by ISO cytotoxicity test that has been used most
   5725 (a program for analysis and reporting of frequently in formal
   validation programs, all of proficiency tests and method evaluation
   studies). which were aimed at evaluation of cytotoxicity in ISO 5725
   describes reproducibility as an estimate predicting eye irritancy.
   Large-scale studies to be of the limit below which the absolute value
   of the mentioned here are Phases I, II, and III of the difference
   between two results determined in two Cosmetic, Toiletry, and Fragrance
   Association different laboratories can be expected to fall, with (CTFA)
   validation program (Gettings et al., 1991, a probability of 95%. The
   value tabulated in the 1992, 1994a, 1994b); the German eye irritation
   far right column in Table 2 represents the span of validation study
   (Spielmann et al., 1991, 1993, about four standard deviations. 1996);
   the European Commission/British Home Office (EC/HO) eye irritation
   validation study (Balls et al., 1995); and the European Cosmetic
   Toiletry and Perfumery Association (COLIPA) eye irritation study
   (Brantom et al., 1997). The 3T3 NRU Phototoxicity Test is a
   modification of the BALB/c 3T3 NRU test and involves a shorter chemical
   exposure and the additional application of light. The 3T3 NRU
   Phototoxicity Test has been fully validated (Spielmann et al., 1998a,b)
   and has gained regulatory acceptance. For the purpose of evaluating the
   NRU test, and specifically the BALB/c 3T3 NRU test, as a standard test
   for basal cytotoxicity, all results available from these studies
   regarding the reliability (reproducibility within and between
   laboratories and over time) should be used to avoid wasting resources
   in repeating the establishment of reliability. Section 4.2 contains an
   example of establishing reliability of the BALB/c 3T3 NRU test from one
   of these studies. 4.2 Reliability of the 3T3 NRU Test To establish
   interlaboratory reproducibility in the first phase of the German eye
   irritation validation study (Spielmann et al., 1991), 32 chemicals were
   tested in 12 laboratories using two tests: the hen's egg
   test-chorioallantoic membrane (HET-CAM) and the BALB/c 3T3 NRU test.
   (NRU tests using 3T3 cells were done in accord with the SOP 15 Using In
   Vitro Data to Estimate In Vivo Starting Doses for Acute Toxicity Table
   2. Interlaboratory reproducibility of the 3T3 NRU cytotoxicity test
   determined according to ISO 5725 in 12 laboratories for 29 chemicals a
   Substance CAS No. NR b 50 Interlaboratory reproducibility c (mg/ml)
   (mg/ml) Dimethylsulphoxide 67-68-5 44.06 18.36 Propylene glycol 57-55-6
   36.27 25.40 Acetone 67-64-1 18.41 14.74 Ethanol 64-17-5 18.01 14.69
   Acetonitrile 75-056-8 13.72 15.38 Sodium chloride 7647-14-5 7.74 3.66
   Thiourea 62-56-6 6.41 5.49 2-Butoxyethanol 111-76-2 5.43 8.73
   Nicotinamide 98-92-0 5.36 5.78 Glutamic acid 56-86-0 4.84 2.01 Lactic
   acid 598-82-3 4.16 1.56 Pyridine 110-86-1 3.71 4.78 Benzoic acid
   65-85-0 3.09 1.67 Isobenzoic furano dione 85-44-9 2.47 0.63
   Cyclohexanol 108-93-0 1.89 2.07 Toluene 108-88-3 1.72 3.96 Salicylic
   acid 69-72-7 1.63 2.04 Tin(II) chloride 7772-99-9 1.55 2.35
   Nitrobenzene 98-95-3 1.39 1.33 Tetrachlorethene 127-18-4 1.08 2.35
   Aniline 62-53-3 1.07 1.25 EDTA-Na salt 13235-36-4 0.95 0.50 Ascorbic
   acid 50-81-7 0.49 0.81 Phenol 108-95-2 0.35 0.74 Acrylamide 79-06-1
   0.29 0.19 Copper (II) sulfate 7758-98-7 0.10 0.05 Sodium lauryl sulfate
   151-21-3 0.093 0.09 2-Propane-1-ol 107-18-6 0.05 0.06 Benzalkonium
   chloride 8001-54-5 0.01 0.01 aFrom Spielmann et al., 1991. bNR50= mean
   concentration of test substance reducing the viability of cells to 50%
   of the viability of controls. cISO 5725 describes reproducibility as an
   estimate of the limit below which the absolute value of the difference
   between two results determined in two different laboratories can be
   expected to fall, with a probability of 95%. 16 Using In Vitro Data to
   Estimate In Vivo Starting Doses for Acute Toxicity The second phase of
   the German eye irritation validation study was a blind trial for
   database development and involved the testing of 150 chemicals
   (Spielmann et al., 1993, 1996). Each chemical was assigned at random to
   two of the 12 total laboratories, since reproducibility of the BALB/c
   3T3 NRU test was not an issue at this stage of the study. The final
   publication (Spielmann et al., 1997) on this phase focused on
   predictivity and test strategies for identification of severe eye
   irritants. The data from this publication have been re-analyzed for the
   present guidance document in the following way: since each chemical was
   tested in two different laboratories, the IC50 values obtained in two
   laboratories were plotted against each other, as shown in Figure 5 for
   147 of the 150 chemicals. (Three chemicals had to be excluded because
   they were not tested according to the SOP.) Note that "Lab 1"
   represents the total of all participating laboratories, as does "Lab
   2". Thus, Figure 5 does not show the comparability of results between
   two given laboratories. Rather, it shows the comparability of data
   obtained under routine conditions between randomly selected
   laboratories performing the BALB/c 3T3 NRU test according to the same
   SOP. Results of the correlation analysis shown in Figure 5 are quite
   promising, since the linear correlation line (black) deviates only
   slightly from the ideal line (gray line at 45Â° angle). The linear
   correlation coefficient of r = 0.88 (R2 = 0.775) shows a sufficient
   comparability of the data. Outliers, where data of the two laboratories
   differed by more than 1 log, occurred for less than 10% of the
   chemicals. A predominant reason for these interlaboratory deviations,
   discussed in Spielmann et al. (1997), was that one laboratory had used
   an adequate solvent for a test chemical, while the other laboratory had
   tested the chemical in media at concentra
